Comparison of the Effect of Ranibizumab and Aflibercept on Changes in Macular Choroidal Thickness in Patients Treated for Diabetic Macular Edema

Table 1

Patient characteristics in aflibercept, ranibizumab, and control eyes.

	Aflibercept group (n = 13)	Ranibizumab group (n = 11)	Control (n = 15)
Age (years)	62.1	60	64.7
Type 2 (number)	11	10	15
Baseline BCVA (letters)	64.5	67.1	75.4
Final BCVA (letters)	72.5	79.1	80.5